Stocks analysis

A vs AEP Stock Comparison

Scores Breakdown

Metric A AEP
📈 Growth 26/30 12/30
💰 Profitability 17/20 14/20
🏦 Financial Health 15/20 14/20
💵 Valuation 16/20 15/20
⚠️ Risk (lower is better) 5/10 5/10
Overall Score 79/100 60/100

Side-by-Side Summaries

A Analysis AEP Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

  • Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
  • Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Across the 8 quarters, Revenues rose from about $4.70B (2024 Q3) to $5.45B (2026 Q2), a ~16% gain, but with volatility (peak around $6.01B in 2025 Q3 and dips in several quarters). Net income ranged from about $0.92B (2024 Q3) to a high of about $1.29B (2025 Q2), ending near $0.75B in 2026 Q2. The trajectory shows modest top-line growth with mixed earnings momentum; the end result is below the initial earnings level despite higher revenue.

💰 Margins & Cash Flow

Operating margins have generally trended in the mid-20s percent across several quarters (roughly mid-20s in 2024 Q4 and 2025 Q3; about 23% in 2026 Q2). Cash flow from operations remained positive in most periods (roughly $1.2B–$1.9B), while investing activities were sizable and often negative, pressuring overall free cash flow. Net cash flow patterns reflect ongoing capital spending typical of a regulated utility.

🛡️ Balance Sheet & Liquidity

Total assets run around $110B–$122B with equity in the $27B–$33B range and long-term debt near $42B–$50B. Liabilities exceed current assets in several quarters, yielding weaker near-term liquidity (current ratio often below 1). Still, a large asset base and regulated cash flows provide resilience, with debt levels offset by steady rate recovery.

⚠️ Key Drivers & Risks

  • Drivers: Regulated utility demand and rate recovery leverage, ongoing energy transition investments.
  • Risks: Interest-rate/regulatory sensitivity and capital-intensity; earnings can remain volatile around quarterly shifts in demand and tax items.